Mounjaro May Reduce the Effectiveness of Oral Contraceptives by Hindering Absorption

Weight Loss and Metabolic Improvement Can Restore Ovulatory Function

Risk of Birth Defects Cannot Be Ruled Out If Used During Pregnancy

"I experienced two miscarriages, but then I became pregnant unexpectedly."


"Due to polycystic ovary syndrome, I haven't menstruated without medication for eight years, but menstruation resumed just three weeks after starting Mounjaro therapy."


These are testimonials posted on online communities and social media regarding the use of obesity medications. In fact, a woman in her 40s in the United States who had suffered from miscarriages and infertility for eight years recently succeeded in becoming pregnant—almost miraculously—after taking the diabetes and obesity medication Mounjaro.


In Korea as well, a woman in her 30s living in Chuncheon, referred to as Ms. A, reported that she returned to a normal menstrual cycle after taking Mounjaro.

Image created using artificial intelligence (AI) to aid understanding of the article. ChatGPT

Image created using artificial intelligence (AI) to aid understanding of the article. ChatGPT

View original image

With more people sharing experiences of unexpected pregnancies while using GLP-1-based obesity treatments, so-called "Mounjaro Babies" and "Ozempic Babies" are increasingly being reported.


Last year, the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) advised women using GLP-1-based medications to be especially cautious regarding pregnancy and contraception. At that time, more than 40 cases were reported to the MHRA in which GLP-1-based drug users had become pregnant unintentionally.


Because tirzepatide, the main ingredient in Mounjaro, slows the movement of food and medications from the stomach to the small intestine, the absorption of oral contraceptives taken together may be insufficient, potentially reducing their effectiveness.


Even women who are not taking oral contraceptives may find their chances of pregnancy increase when using obesity treatments. This is because weight loss and improved metabolism can help restore previously irregular ovulatory function.


In particular, women with polycystic ovary syndrome or obesity are often more insulin resistant, and high insulin levels stimulate the ovaries to secrete more male hormones, leading to ovulatory disorders. When GLP-1-based medications are used, weight loss and improved insulin resistance occur, male hormone secretion decreases, and regular ovulation can be restored.


However, experts strongly caution that the increased likelihood of pregnancy after taking obesity medications requires extra attention. If a woman continues the medication without knowing she is pregnant, the fetus may be exposed to these drugs. Animal studies have shown that exposure to GLP-1 drugs increases the risk of fetal malformations or death.



Although sufficient clinical trial data for humans is not yet available, the medical community judges that these risks cannot be ruled out. Current obesity drug product information explicitly states that "the safety of the medication for the fetus during pregnancy has not been established."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing